Neurogene Inc. 8-K

What Happened

• Neurogene Inc. announced on June 8, 2026 (via an 8-K Regulation FD disclosure) that it has completed dosing in its Embolden registrational trial of NGN-401, an investigational gene therapy for Rett syndrome. The company issued a press release and posted an updated corporate presentation the same day.

Key Details

• Completion of dosing in the Embolden registrational trial for NGN-401 was announced on June 8, 2026.
• Announcement disclosed via press release (furnished as Exhibit 99.1) and an updated corporate presentation posted to the company website (furnished as Exhibit 99.2).
• The Form 8-K was signed by Christine Mikail, President and Chief Financial Officer, and filed under Regulation FD (Item 7.01).

Why It Matters

• Completing dosing is a major clinical milestone for a registrational trial: it typically signals the study has finished treating participants and moves the program closer to data readouts and potential regulatory interactions.
• For investors, this reduces near-term clinical execution uncertainty and focuses attention on upcoming safety and efficacy results, timing of topline data, and any subsequent regulatory plans the company may disclose.